Spectrum Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
SPPI Spectrum Pharmaceuticals Inc
NMXS Net Medical Xpress Solutions Inc
ARKG ARK Genomic Revolution ETF
BWA Borgwarner Inc
RCG RENN Global Entrepreneurs Fund, Inc.
SPI SPI Energy Co Ltd
CLH Clean Harbors Inc
CNLMF Collective Mining Ltd
ERIC Telefonaktiebolaget LM Ericsson
DVN Devon Energy Corp
Go

Health Care : Biotechnology | Small Cap Value
Company profile

Spectrum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's product portfolio consists of in-development drug products for the treatment of cancer patients. Its pipeline products include ROLONTIS, Poziotinib and Anti-CD20-IFNa. ROLONTIS (eflapegrastim injection), is a long-acting granulocyte colony-stimulating factor (G-CSF) for chemotherapy-induced neutropenia. Poziotinib, is a pan-HER inhibitor that irreversibly blocks signaling through the Epidermal Growth Factor Receptor (EGFR) family of tyrosine-kinase receptors, including HER1 (erbB1; EGFR), HER2 (erbB2), HER4 (erbB4), and HER receptor mutations. Anti-CD20-IFNa, is an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for treating relapsed or refractory non-Hodgkin's lymphoma (NHL) patients.

Premarket

Last Trade
Delayed
$1.40
0.03 (2.19%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$1.37
Day's Change
0.00 (0.00%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
39,451

10-day average volume:
6,727,015
39,451

SPPI's position in the Biotechnology industry

Industry PeersSPPICHRSEGRXPARD

Summary

Company ProfileSpectrum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's product portfolio consists of in-development drug products for the treatment of cancer patients. Its pipeline products...
Coherus BioSciences, Inc. is a commercial stage biotherapeutics company. The Company is focused on the biosimilar and immuno-oncology market primarily in the United States. The Company’s pipeline...
Go to CHRS summary
Eagle Pharmaceuticals, Inc. is an integrated pharmaceutical company. The Company takes a molecule from preclinical research through regulatory approval and into the marketplace, including...
Go to EGRX summary
Poniard Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of oncology products to impact the lives of people with cancer. It develops...
Go to PARD summary
52-Week Change

VS. INDUSTRY
-71.87%
-6.28%
-0.19%
-67.74%
Market Cap

VS. INDUSTRY
$224.6M
$1.4B
$612.4M
$15.0K
Beta

VS. INDUSTRY
1.9
1.0
0.6
1.2
Dividend Yield

VS. INDUSTRY
--
--
--
--
P/E (TTM, GAAP)

VS. INDUSTRY
--
--
114.39x
--
Data as of

Fundamentals

Total Revenue (TTM)

VS. INDUSTRY
$0.0
$363.6M
$179.1M
$0.0
Profit Margin

VS. INDUSTRY
--
-63.71%
3.14%
--
Earnings Growth
(5 year, GAAP)

VS. INDUSTRY
--
--
40.65%
--
Revenue Growth (TTM)

VS. INDUSTRY
--
-25.68%
-3.76%
--
Data as of
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Copyright © 2021. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.